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Edited by Gianni CesareniAbstract CFTR exon 9 presents a 3 0 splice site polymorphism,
(UG)mUn, whose composition inﬂuences splicing. TDP43 specif-
ically binds the UG tract of the transcript and inhibits splicing
in vitro. We report that depletion of TDP43 through RNA inter-
ference removes splicing inhibition caused by unfavorable (UG)-
mUn sequences, indicating that TDP43 exerts a potent inhibitory
eﬀect in vivo. We also show that the UG–TDP43 interaction has
a dominant role over other exon 9 splicing regulatory elements.
These results suggest that TDP43 association near a splice site
has determined the evolution of positive splicing regulatory ele-
ments to contrast this inhibition.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cystic ﬁbrosis (CF) is caused by mutations in the cystic ﬁbro-
sis transmembrane conductance regulator (CFTR) gene [1,2].
One of the causes for CF is the skipping of CFTR exon 9, which
results in a nonfunctional protein [3]. Exon 9 recognition ismod-
ulated by a characteristically high number of exonic and intronic
elements with enhancer and silencer splicing properties, among
these is the (TG)mTnpolymorphismat the 3
0 splice site.Unfavor-
able (TG)mTn compositions are linked to the occurrence of
non-classical or mild forms of CF and particularly to the devel-
opment ofmale sterility.When compared to healthy individuals,
patients more often carry a high number of TG repeats (11–13)
and a short T tract (65) [4]. In addition, variousmutations with-
in the exon may have unexpected deleterious eﬀects on splicing
due to the intrinsicallyweakdeﬁnition of this exon.Among these
are mutations in composite exonic regulatory elements of splic-
ing (CERES) that disrupt positive regulatory elements and thus
result in exon skipping (e.g., A455E) [5]. Other regulatory
sequences are located in the downstream intron and act as
enhancer and silencer elements by recruiting the splicing factor
TIA-1 (T cell intracellular antigen-1) [6], and the splicing factor
2/alternative splicing factor (SF2/ASF) [7], respectively.
We have earlier shown that the TAR DNA binding protein
(TDP43) regulates exon 9 splicing, most likely through the
association with the UG repeats at the 3 0 splice site [8].
TDP43 belongs to the family of the heterogeneous nuclear
ribonucleoproteins (hnRNPs) and is highly conserved among
metazoans both in sequence and function [9,10]. The proteins*Corresponding author. Fax: +39 040 3757361.
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repeats with aﬃnities in the low nanomolar range [9,11]. In hu-
man cells, overexpression of TDP43 decreases exon 9 recogni-
tion and speciﬁcally causes exon skipping in vitro [8,12].
Here, we investigate the eﬀect of TDP43 depletion on exon 9
recognition in vivo with the use of RNA interference. Our re-
sults indicate that TDP43 is responsible for CFTR exon 9 skip-
ping in the presence of unfavorable (UG)mUn sequences and
that the protein plays a dominant role over other exonic or in-
tronic regulatory elements. Consistent with these observations,
TDP43 downregulation in patient cells carrying the (TG)13T3
locus signiﬁcantly improves the levels of exon 9 inclusion.
Moreover, removal of TDP43 results in proper exon 9 recogni-
tion despite disruption of enhancer elements or addition of
inhibitory factors.2. Materials and methods
2.1. Cell culture and transfection
Duplex RNA oligonucleotide was synthesized (Dharmacon) against
the target sequence AAGCAAAGCCAAGAUGAGCCU (siR-
NATDP43+). siRNA against the ﬁreﬂy luciferase gene (siCONTROL
Non-Targeting siRNA #2) was used as a nonspeciﬁc control
(siRNATDP43). Cells were transfected as recently described [13].
One microgram of minigene constructs were cotransfected during the
second siRNA transfection. EBV transformed lymphocytes from con-
trol and patient [8] were electroporated as described elsewhere [14].
Cells were collected 36 h after transfection with RNAwiz and total
RNA was isolated according to manufacturer instructions. The
TDP43 recognizing antibody was described earlier [8] and mouse
monoclonal antibody was used to detect tubulin as control (T5168 Sig-
ma). SF2/ASF expression vectors were described earlier [7].2.2. Minigene constructs
The hCF-(TG)(T) minigenes and mutant C1496A, C1496G, and
C1496T constructs have been previously described [5,7]. The mutation
in the intronic splicing enhancer used was earlier referred to as M1,2,3
[6].2.3. Splicing analysis
Splicing eﬃciency was carried out as previously described [7]. Quan-
tiﬁcation of PCR products was carried out according to Pagani et al.
[5]. In the case of endogenous CFTR transcript analysis, the products
were ampliﬁed with primers speciﬁc for exons 8, 10, and 11. Allele spe-
ciﬁc ampliﬁcation from patient cells was carried out with reverse prim-
ers described in Fig. 3. The relative levels of exon inclusion were
visualized on 2% agarose gels.
2.4. Sequence similarity of CFTR exon 9 and surrounding introns from
diﬀerent organisms
Nucleotide sequence alignment of the CFTR exon 9 including ﬂank-
ing introns from diﬀerent mammals was performed. We analyzed se-
quences (NCBI) from human, macaca, chimpanzee, baboon, lemur,
rabbit, armadillo, cat, horse, cow, hedgehog, pig, dog, mouse, and rat.blished by Elsevier B.V. All rights reserved.
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3.1. TDP43 knockdown removes splicing inhibition through UG
repeats
To test the eﬀect of TDP43 on exon 9 splicing in transient
expression in vivo, we depleted the protein through RNA
interference in the presence of minigene constructs containing
variations of the (TG)mTn sequence at the 3
0 splice site. These
sequences are associated with non-classical or mild CF
(TG11–13T3–5). Protein silencing resulted in >90% removal of
TDP43 as indicated by Western blotting (Fig. 1A). CFTR exon
9 inclusion was detected using hybrid minigenes (Fig. 1B) pre-
viously described to successfully mimic the splicing pattern of
endogenous exon 9 CFTR [7,8,15]. The minigenes were trans-
fected into HeLa cells in the presence of control and TDP43-
targeted small interfering (si)RNA and the relative levels of
exon inclusion were monitored by RT-PCR. In agreement with
previous studies, we obtained a high proportion of exon skip-
ping in the presence of high number of UG repeats and a short
U tract. In addition, UG13U3 leads to the activation of a cryp-
tic 3 0 splice site [8]. In the absence of TDP43, however, exon
skipping was signiﬁcantly reduced even in the presence of the
extreme UG13U3 sequence, and splicing through the cryptic
3 0 splice site no longer occurred (Fig. 1C, upper panels). InFig. 1. In vivo depletion of TDP43 by RNAi restores exon 9 inclusion despi
cells treated with TDP43 siRNA, control ﬁreﬂy luciferase siRNA, and mo
constructs. The large arrow represents the promoter site, black boxes rep
ampliﬁcation. (C) a2-3 and BRA primers were used for transcript ampliﬁ
treatment. Top and lower bands correspond to complete exon 9 inclusion an
lane corresponds to the activation of a cryptic 3 0 splice site. Primers a2-3 and
the (TG)13T3 construct. As a control, the eﬀect of TDP43 siRNA was tested
neuroﬁbromin 1 (NF1) gene carrying a mutation that leads to the skippingfact, speciﬁc ampliﬁcation of the transcript containing the
aberrant exon, showed the absence of cryptic site usage in
TDP43 cells (Fig. 1C, lower left panel). As previously ob-
served, deletion of the UG tract (DTG) resulted in complete
exon 9 inclusion and as expected, removal of TDP43 had no
eﬀect on splicing (Fig. 1C, upper right panel). To rule out a
non-speciﬁc eﬀect of TDP43 RNAi depletion on splicing regu-
lation, we analyzed the splicing of an unrelated minigene con-
struct that lacks UG repeats near 3 0 splice sites and normally
shows exon skipping. A variant of exons 34–38 of the neuroﬁ-
bromin 1 gene containing a mutation in exon 37 results in the
skipping of exon 37 and exons 36 and 37 (M. Baralle, personal
communication). Unlike the case of CFTR exon 9, the pattern
and relative proportion of exon skipping of the NF1 mutant
was not inﬂuenced by the depletion of TDP43 (Fig. 1C, lower
right panel).
3.2. Downregulation of TDP43 rescues endogenous exon 9
skipping from wild type and patient cells
Next, we asked whether TDP43 removal by RNAi would
similarly aﬀect the splicing of the chromosomal CFTR exon
9. We used wild type HeLa, Hep3B, and lymphoblasts. These
cells generate 10–20% exon 9 transcript, consistent with the
variability in the level of exon exclusion observed amongte unfavorable (TG)mTn sequences. (A) Western blot analysis of HeLa
ck transfection. (B) Schematic representation of the hybrid minigene
resent non-CFTR exons, and small arrows depict primers used for
cation from (TG)13T3 ,(TG)13T5, and DTG constructs upon RNAi
d exclusion, respectively. The middle band present in (TG)13T3 control
crp were used to speciﬁcally monitor 3 0 cryptic splice site activation of
on an unrelated hybrid minigene system containing exons 34–38 of the
of one or two exons.
Fig. 2. TDP43 depletion removes endogenous exon 9 skipping. HeLa, Hep3B, and wild type lymphoblasts were transfected with siRNA. The upper
and lower bands represent the exon 9 included and excluded products, respectively.
Y.M. Ayala et al. / FEBS Letters 580 (2006) 1339–1344 1341healthy individuals [16] (Fig. 2). TDP43 removal from these
cells induced 100% inclusion of exon 9. We then analyzed lym-
phoblasts derived from a previously identiﬁed CF patient who
carried the TG13T3 sequence in one allele and TG10T9 plus the
DF508 exon 10 mutation in the other. Earlier studies showed
that exon 9 splicing is severely aﬀected by the TG13T3 sequence
at the 3 0 splice site in these cells [8]. Our present ﬁndings indi-
cate that downregulation of TDP43 in this cell line resulted in
the recovery of exon 9 inclusion compared to control treated
cells (Fig. 3B). As observed earlier [8], the degree of exon 9
inclusion from the DF508 allele should be similar to wild type,
instead, it is unexpectedly low in these cells. For the purpose of
these studies, we concentrated on the eﬀect of TDP43 down-
regulation on the allele aﬀected by the TG13T3 sequence only.
To monitor the recovery of exon 9 inclusion from each of the
alleles independently, PCR ampliﬁcation was carried out with
speciﬁc primers for the 3 0 end within exon 10 designed to an-
neal to the TG13T3 (wild type sequence in exon 10) or to the
TG10T9 (DF508 mutated) allele (scheme shown in Fig. 3A).
Fig. 3C shows that in the presence of TDP43(siRNATDP43),
the TG13T3 allele speciﬁc primer did not detect exon 9 contain-
ing transcripts, while exon 9+ transcripts, ampliﬁed with a
DF508 speciﬁc primer, are present. Down-regulation of
TDP43 (+siRNATDP43) showed a signiﬁcant increase in the
levels of exon 9 splicing from the TG13T3 allele. Exon 9 inclu-
sion from the DF508 allele was also increased, as observed with
the endogenous exon 9 from the control cells (Fig. 2). WhenFig. 3. TDP43 siRNA transfection of patient cells expressing the TG13T
lymphocytes obtained from a patient carrying the TG13T3 polymorphism in
siRNA. (A) Schematic representation of the CFTR gene between exons 8 an
sequence used to speciﬁcally amplify alleles wtF508 and DF508. (B) Upon
ampliﬁed both alleles indistinguishably. (C) Speciﬁc ampliﬁcation of the TG1
treated cells. (D) Western blot analysis of transfected patient cells.compared to the extent of exon 9 splicing rescue upon siR-
NATDP43 treatment in Hep3B and HeLa cell lines (endogenous
or minigene exon 9), the increase in exon 9 inclusion in lym-
phoblasts was lower. This diﬀerence may be explained by the
lower eﬃciency of siRNA transfection of the lymphoblasts
by means of electroporation compared to liposomal transfec-
tion of the other cells studied (compare Western blots Figs.
1A and 2D). Nevertheless, a substantial exon 9 splicing
improvement was observed in the patient lymphoblasts, sug-
gesting that ﬁne-tuning of TDP43 expression could modulate
the CF phenotype.
3.3. Dominant role of TDP43 over other splicing regulatory
elements
We then studied the interaction between TDP43 and other
elements that determine exon 9 splicing. Among the previously
mapped regulatory sequences, we chose two enhancer elements
and an intronic splicing silencer. One of the positive elements,
found in the exon, can be aﬀected by a naturally occurring
mutation associated with CF (A455E). The disruption results
from a C to A change at nucleotide position 1496 which in-
creases the levels of exon skipping [5]. Changes to every other
nucleotide also prevent exon inclusion. The other positive ele-
ment is located in the downstream intron and is composed of
three polypyrimidinic tracts whose disruption causes splicing
inhibition when combined with (UG)11U5 and (UG)13U3 [6].
These polypyrimidine-rich controlling elements (PCE) bind3 polymorphism increases inclusion of exon 9. Virally transformed
one allele and TG10T9/DF508 (exon 10) in the other were treated with
d 11 outlining the location of the primers used for PCR, including the
RNAi treatment, exon 9 inclusion was monitored with primers that
3T3 or TG10T9 alleles (primers ex8F and wtF508/DF508) from siRNA
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exon inclusion with constructs carrying disruptions in the po-
sitive regulatory elements in a (UG)11U5 background in the
presence and absence of TDP43 (Fig. 4B). The naturally occur-
ring substitution C1496A resulted in greater than 50% reduc-
tion of exon 9 splicing in control cells. TDP43-siRNA
treated cells rescued the splicing defect showing near 100% lev-
els of exon inclusion. Removal of TDP43 generated similar res-
cue patterns in the case of C1496T and to a lesser extent in the
case of C1496G. This last substitution resulted in the highest
levels of skipping among the diﬀerent mutants because it has
been shown to not only disrupt a positive element, but to cre-
ate an inhibitory signal as well [5]. The continuous sequence of
guanines (G5) recruits hnRNP H which acts as a splicing inhib-
itor at this site. Nevertheless, TDP43 depletion induced a sig-
niﬁcant improvement in exon recognition despite the
presence of hnRNP H. In the case of the intronic PCE, muta-
tion of all three downstream elements (Fig. 4A) resulted in
60% of exon exclusion in control cells, while TDP43 depleted
cells showed little or no exon skipping (Fig. 4B).
Further downstream of the PCE in intron 9, a negative reg-
ulatory sequence was identiﬁed and its function is associated
with SF2/ASF overexpression [7]. We examined the eﬀect of
augmenting exon 9 exclusion through overexpression of SF2/
ASF in the absence of TDP43. Skipping of exon 9 increased
in control cells overexpressing SF2/ASF, while upon removal
of TDP43, 100% exon inclusion was observed in both samples
(Fig. 4C). Thus suggesting that changes in SF2/ASF cellular
concentration have no inhibitory eﬀect when TDP43 is absent.
Collectively our results imply that TDP43 binding near the 3 0Fig. 4. TDP43 inhibition of exon 9 recognition is dominant over surround
elements was determined in the presence and absence of RNAi. (A) Loca
elements are shown. The nucleotide sequences of the wild type and mutant P
mPCE are reported. (C) Control and TDP43 depleted cells were cotransfecte
and SF2/ASF overexpression were analyzed in a (TG)11T5 background. The
[5].splice site weakens exon 9 deﬁnition, causing exon inclusion to
be particularly sensitive to nucleotide substitutions at modula-
tory sites (C1496 or PCE) and to changes in the expression lev-
els of other regulatory factors such as SF2/ASF.4. Discussion
The aberrant splicing of CFTR exon 9 has been closely scru-
tinized due to its role in the occurrence of classical and non-
classical forms of cystic ﬁbrosis. At the same time, the studies
have revealed an unusual complexity in the regulation of splic-
ing. One of the key modulators of exon inclusion is the
(TG)mTn polymorphism at the 3
0 splice site. This unusual 3 0
splice site structure is found in the CFTR exon 9 of Old World
monkeys and Hominidae. Analyses of sequences deposited in
the databanks indicate that most other organisms, including le-
mur, have predictably eﬃcient, longer pY tracts, not inter-
rupted by TG (see Section 2). The species-speciﬁc presence of
the TG element may be ascribed to a retrotransposition event
upstream of exon 9 CFTR [17]. This circumstance might have
fortuitously lowered exon deﬁnition providing the basis for
non-functional exon skipping in CFTR mRNA and the subse-
quent development of CF phenotypes. Through the use of
RNAi, we now determined that the splicing factor TDP43,
which binds the (UG)m sequence, plays a dominant inhibitory
role in vivo that overrides previously identiﬁed regulatory ele-
ments. Our observations clearly demonstrate that when
TDP43 is depleted, normal exon 9 splicing occurs despite the
presence of unfavorable UG/U compositions. These observa-ing splicing regulatory elements. The eﬀect of mutations in enhancer
tion of enhancer (1496 and PCE) and intronic splicing silencer (ISS)
CE (mPCE) [6] are included. (B) Results from 1496 substitutions and
d with 1 lg of SF2/ASF (+) or empty expression vector (). Mutations
values below each lane represent the quantiﬁed levels of exon inclusion
Y.M. Ayala et al. / FEBS Letters 580 (2006) 1339–1344 1343tions provide deﬁnite proof that the variable penetrance of the
UG repeats is due to an RNA–protein interaction rather than
being determined by RNA secondary structure, as was also
suggested [18]. Changes in TDP43 tissue concentration, along
with an unfavorable UG/U conﬁguration, are likely to be the
most important determinants of the CF phenotype variability
associated with exon 9 splicing. Our ﬁndings suggest that
TDP43 may be a reasonable therapeutic target to correct for
aberrant skipping of exon 9. Moreover, mutations in enhancer
elements or the presence of inhibitory factors that control
CFTR exon 9 splicing have no eﬀect upon removal of
TDP43. Therefore, TDP43 downregulation would also im-
prove CFTR expression in cases of positive splicing element
disruption, such as in the A455E (C1496A) mutation.
The accidental recruitment of TDP43 to the UG tract most
likely prevents assembly of critical splicing factors in the pres-
ence of short polythymidine tracts at the 3 0 splice site, whose
identiﬁcation by the spliceosome machinery requires the pres-
ence of classical splicing factors (i.e., U2snRNP, U2AF,
branch point binding protein) [19]. The positive splicing mod-
ulators recruited by the enhancer elements may antagonize
TDP43 binding to the UG element (Fig. 5). As suggested by
our ﬁndings, the situation changes drastically in the absence
of TDP43: spliceosome assembly may take place correctly, de-
spite the presence of unfavorable pY tracts, and nucleotide
substitutions in enhancer sequences no longer become associ-
ated with exon skipping. This model is also supported by re-
cent ﬁndings regarding the role of TDP43 on the splicing of
exon 3 of the apolipoprotein AII [13]. We speculate that the
presence UG repeats near 3 0 splice sites, and therefore
TDP43 recruitment, requires surrounding positive regulatoryFig. 5. Model of splicing inhibition by TDP43 binding adjacent to the
3 0 splice site including the interactions of the enhancer elements located
in the exon and in intron 9 of CFTR. The upper panel depicts TDP43
block of exon recognition, while the lower panel represents the
situation in the absence of the inhibitor.elements to promote exon recognition. It would be interesting
to examine whether exon 9 CFTR from species lacking the
(TG)m element have functional homologues of the human en-
hancer sequences.Acknowledgments: Y.M.A. is a National Science Foundation Minority
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